Adenosine A2A receptor antagonist DZD-2269 overcomes adenosine-induced immunosuppression Nov. 20, 2019
Preliminary clinical data on CRISPR/Cas9 gene-editing therapy CTX-001 in severe hemoglobinopathies Nov. 20, 2019
Phase III dosing defined for lixivaptan in autosomal dominant polycystic kidney disease Nov. 20, 2019
Phase III study of vericiguat in worsening chronic heart failure meets primary endpoint Nov. 20, 2019
RSS